Mantle Cell Lymphoma: A Clinically Heterogeneous Disease in Need of Tailored Approaches
Bijal Shah(Boston College), Eduardo M. Sotomayor(Tampa General Hospital), Peter Martin(Northwestern University)
Cited by 44
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
|The Journal of Immunology|2001|533